Supernus Pharmaceuticals beat analysts’ revenue expectations by 12.2% last quarter, reporting revenues of $174.2 million, up 6% year on year. It was a very strong quarter for the company, with ...

Supernus Pharmaceuticals' stock has risen 15% since my last "strong buy" rating, despite recent analyst downgrades due to Qelbree's slowing growth. Supernus' diverse neuroscience portfolio ...

A new Supernus Pharmaceuticals medical device that continuously administers an old Parkinson’s disease drug is now FDA approved, giving patients another way to manage the motor control symptoms ...

Mumbai: Lupin Limited has announced that it has received tentative approval from the United States Food and Drug ...

Supernus Pharmaceuticals Inc., a Rockville-based pharmaceutical company focused on products for the treatment of central nervous system diseases, reported ...

Supernus' reliance on Qelbree is increasing, with significant revenue growth in 2024, but generic competition for other drugs poses challenges. Management's 2025 guidance led to a stock sell-off ...

ROCKVILLE, Md., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of ...

May 29, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals is expanding its partnership with TV personality and sports reporter Jay Glazer in a new content series featuring his wife, Rosie Glazer.

Supernus Pharmaceuticals, Inc. Qelbree ® net product sales growth of 179% and 193% in the first three months and first six months of 2023, respectively, compared to the same periods in 2022 $31.0 ...